Opinion
Video
Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups